SS-31 dosage: reported doses and schedule
A peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven.
Also called: Elamipretide, SS31, SS 31, MTP-131, Bendavia, Forzinity.
Mitochondria-targeted peptides · Mitochondrial cardiolipin-binding tetrapeptide · Evidence: Approved drug.
Typical reported dose: 40 mg once a day
- Forzinity: labelled daily dose: 40 mg subcutaneously once daily once daily, under the skin. Drug label. Studied in: Barth syndrome, body weight at least 30 kg. (source)
- Forzinity: severe kidney impairment: 20 mg subcutaneously once daily once daily, under the skin. Drug label. Studied in: Adults with Barth syndrome, ≥30 kg, eGFR <30 mL/minute and not on dialysis. (source)
- MMPOWER: low IV dose: 0.01 mg/kg/hour IV for 2 hours daily; 0.02 mg/kg total per day once daily as a 2-hour infusion, into a vein. Studied in a trial. Studied in: Adults with genetically confirmed primary mitochondrial myopathy. (source)
- MMPOWER: middle IV dose: 0.1 mg/kg/hour IV for 2 hours daily; 0.2 mg/kg total per day once daily as a 2-hour infusion, into a vein. Studied in a trial. Studied in: Adults with genetically confirmed primary mitochondrial myopathy. (source)
- MMPOWER: high IV dose: 0.25 mg/kg/hour IV for 2 hours daily; 0.5 mg/kg total per day once daily as a 2-hour infusion, into a vein. Studied in a trial. Studied in: Adults with genetically confirmed primary mitochondrial myopathy. (source)
- MMPOWER-2: 40 mg: 40 mg SC once daily once daily, under the skin. Studied in a trial. Studied in: Adults with genetically confirmed primary mitochondrial myopathy. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to SS-31 (elamipretide)
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- NAD+ and precursors: NAD+ helps cells use energy; wellness injection benefits remain unproven.
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- MHRA-101705-PIP01-24 | MHRA, 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- TGA warning on the risks of importing unapproved peptide products, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Darmerica, LLC - 716152 - 12/08/2025, FDA · FDA · 2025
- FORZINITY (elamipretide) injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- NDA 215244 Forzinity (elamipretide): Integrated Review, 2025
- EU/3/21/2430 - orphan designation for treatment of Barth syndrome | European Medicines Agency (EMA), 2021
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.